TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19415672

Group type: EXPERIMENTAL
Intervention: Walking exercise
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Stretching exercise
Number of subjects: 124
Study: 17451506

Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride (AmF/SnF(2)) mouthrinse used daily for 3 weeks
Number of subjects: 30
Study: 15844402

Group type: COMPARATOR
Intervention: Anorexic patients
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Normal subjects
Number of subjects: 11
Study: 11386644

Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.2 mg/mL applied intraoperatively for 5 minutes)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no mitomycin C)
Number of subjects: 16
Study: 9893104

Group type: EXPERIMENTAL
Intervention: Blood samples drawn on Mondays
Number of subjects: 209

Group type: COMPARATOR
Intervention: Blood samples drawn on non-Mondays
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Participants starting and ending on a Monday
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Participants who changed the day of examination from Monday to non-Monday or vice versa
Number of subjects: 209
Study: 8038981

Group type: EXPERIMENTAL
Intervention: Intravenous propofol 10 mg (group I)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1 ml intralipid (group II)
Number of subjects: 50
Study: 2740681

Group type: EXPERIMENTAL
Intervention: Single-dose Ceftriaxone (2 grams)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cefamandole (multiple doses)
Number of subjects: 0
Study: 1221098

Group type: EXPERIMENTAL
Intervention: Antifibrinolytic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Drug induced hypotension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined treatment (drug induced hypotension and antifibrinolytic therapy)
Number of subjects: 0
Study: 31521682

Group type: EXPERIMENTAL
Intervention: CABG + optimal medical therapy
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 1212
Study: 28339282

Group type: EXPERIMENTAL
Intervention: Melatonin with olanzapine and lithium carbonate
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo with olanzapine and lithium carbonate
Number of subjects: 48
Study: 25290104

Group type: EXPERIMENTAL
Intervention: Cycloidal vibration therapy applied to the knee extensors twice daily for 7 days
Number of subjects: 50

Group type: COMPARATOR
Intervention: Stretching and sports massage (SSM) performed twice daily for 7 days
Number of subjects: 50
Study: 23272987

Group type: EXPERIMENTAL
Intervention: Mindfulness therapy
Number of subjects: 119

Group type: COMPARATOR
Intervention: Enhanced treatment as usual
Number of subjects: 119

Group type: COMPARATOR
Intervention: Mindfulness therapy and Enhanced treatment as usual
Number of subjects: 119

Group type: COMPARATOR
Intervention: BDS patients
Number of subjects: 119
Study: 21480731

Group type: EXPERIMENTAL
Intervention: 7 mg transdermal nicotine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18022787

Group type: EXPERIMENTAL
Intervention: Verbal consent (n = 100)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Limited written consent (n = 100)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Detailed written consent with signature (n = 100)
Number of subjects: 300
Study: 16412159

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sumatriptan 25 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12897045

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation (beta-carotene: 6 mg, vitamin C: 120 mg, vitamin E: 30 mg, zinc: 20 mg, selenium: 100 micro g)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Micronutrient supplementation
Number of subjects: 106
Study: 10726050

Group type: EXPERIMENTAL
Intervention: 75 U anti‐Xa/kg BW (actual range 63 to 91) once daily started 12 hours before operation
Number of subjects: 250

Group type: COMPARATOR
Intervention: 50 U anti‐Xa/kg BW (actual range 41 to 71) once daily started 2 hours before operation
Number of subjects: 250
Study: 9374602

Group type: EXPERIMENTAL
Intervention: Confessions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eyewitness identification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Character testimony
Number of subjects: 0

Group type: COMPARATOR
Intervention: No evidence
Number of subjects: 0
Study: 1439060

Group type: EXPERIMENTAL
Intervention: Nicotine gum (active treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicotine gum (placebo)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acupuncture (active treatment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acupuncture (placebo)
Number of subjects: 0
Study: 3803821

Group type: EXPERIMENTAL
Intervention: Zinc sulfate, 200 mg daily for 2 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: No supplementation (control group)
Number of subjects: 38
Study: 31092661

Group type: EXPERIMENTAL
Intervention: Occupational distress (psychiatric morbidity, burnout, job effort, work-life imbalance, coping with stress through self-blame or substances)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Occupational distress
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Burnout
Number of subjects: 417
Study: 30107809

Group type: EXPERIMENTAL
Intervention: Milestones Communication Approach (MCA)
Number of subjects: 100
Study: 26920137

Group type: EXPERIMENTAL
Intervention: NOVOCART™ Disc plus autologous disc chondrocyte transplantation
Number of subjects: 120
Study: 25061313

Group type: EXPERIMENTAL
Intervention: Aliskiren-based therapy
Number of subjects: 154

Group type: COMPARATOR
Intervention: Ramipril-based therapy
Number of subjects: 154
Study: 21862331

Group type: EXPERIMENTAL
Intervention: Letrozole plus trastuzumab (Arm B)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Letrozole alone (Arm A)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Letrozole alone (Arm C)
Number of subjects: 92
Study: 19574783

Group type: EXPERIMENTAL
Intervention: HPV 16/18 AS04-adjuvanted vaccine
Number of subjects: 0
Study: 18160685

Group type: EXPERIMENTAL
Intervention: Defibrillator implantation plus adjunctive catheter ablation
Number of subjects: 128

Group type: COMPARATOR
Intervention: Defibrillator implantation alone
Number of subjects: 128
Study: 15724802

Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 16
Study: 12479190

Group type: EXPERIMENTAL
Intervention: Remifentanil TCI at 19 ng x ml(‐1) reduced to 10 ng x ml(‐1) after 1 min
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil TCI at 15 ng x ml(‐1) reduced to 8 ng x ml(‐1) after 1 min
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil TCI at 11 ng x ml(‐1) reduced to 6 ng x ml(‐1) after 1 min
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol TCI at 6.5 microg x ml(‐1) reduced to 3 microg x ml(‐1) after 1 min
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Post-laryngoscopy measurements
Number of subjects: 60
Study: 9716198

Group type: EXPERIMENTAL
Intervention: Bailout coronary stenting
Number of subjects: 50
Study: 7926230

Group type: EXPERIMENTAL
Intervention: Cefuroxime 1500 mg
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cefuroxime 750 mg
Number of subjects: 39
Study: 2513859

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1099263

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ephedrine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Theophylline + Ephedrine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Theophylline + Ephedrine + Hydroxyzine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 30998547

Group type: EXPERIMENTAL
Intervention: Strong signal processing hearing aid fitting
Number of subjects: 49

Group type: COMPARATOR
Intervention: Mild signal processing hearing aid fitting
Number of subjects: 49
Study: 28512047

Group type: EXPERIMENTAL
Intervention: Computer-assisted lateral entry point approach
Number of subjects: 68

Group type: COMPARATOR
Intervention: Traditional transpedicle approach
Number of subjects: 68
Study: 25381471

Group type: EXPERIMENTAL
Intervention: Acute group (3-7 weeks post-injury)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Chronic group (6-11 months post-injury)
Number of subjects: 55
Study: 23455863

Group type: EXPERIMENTAL
Intervention: Nasal bridle
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (traditional adhesive tape)
Number of subjects: 50
Study: 21801537

Group type: EXPERIMENTAL
Intervention: The Hip & Knee Book
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control booklet
Number of subjects: 119
Study: 19397673

Group type: EXPERIMENTAL
Intervention: Deoxycholate
Number of subjects: 42

Group type: COMPARATOR
Intervention: Phosphatidylcholine/deoxycholate
Number of subjects: 42
Study: 16466599

Group type: EXPERIMENTAL
Intervention: Inert cellulose powder
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 15131556

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 49)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (n = 39)
Number of subjects: 88
Study: 11677548

Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: McGill Pain Questionnaire
Number of subjects: 75
Study: 9222726

Group type: EXPERIMENTAL
Intervention: Undetectable total IgA (< 0.07 g/l) as a selection criterion for small bowel biopsy
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Serum IgA levels in patients with AGA 0-10 ELISA units (EU)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Comparison of median IgA levels
Number of subjects: 318

Group type: COMPARATOR
Intervention: Controls with AGA 0-10 EU
Number of subjects: 318
Study: 8228209

Group type: EXPERIMENTAL
Intervention: lacto-ovovegetarian diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: omnivorous diet
Number of subjects: 20
Study: 3630597

Group type: EXPERIMENTAL
Intervention: Intrapleural administration of bupivacaine-adrenaline solution (10 or 20 ml of 2.5 mg/ml or 5 mg/ml)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Intrapleural administration of bupivacaine-adrenaline solution
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (NaCl) given intrapleurally
Number of subjects: 21
Study: 31366415

Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control intervention (10-session home-visiting intervention)
Number of subjects: 105
Study: 29020861

Group type: EXPERIMENTAL
Intervention: High-dose psilocybin (20 mg/70 kg and 30 mg/70 kg) with standard support (HD-SS)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High-dose psilocybin (20 mg/70 kg and 30 mg/70 kg) with high support (HD-HS)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Very low-dose psilocybin (1 mg/70 kg) with standard support (LD-SS)
Number of subjects: 75
Study: 26928904

Group type: EXPERIMENTAL
Intervention: Low-equol group (10 mg/d)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: High-equol group (20 mg/d)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 207
Study: 25229781

Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 21

Group type: COMPARATOR
Intervention: Intense pulsed light (IPL)
Number of subjects: 21
Study: 22744655

Group type: EXPERIMENTAL
Intervention: Hematoma growth (absolute increase of 10.7 mL over 24 hours)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Hematoma growth (relative growth)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Hematoma growth (1 mL increase)
Number of subjects: 335
Study: 19258442

Group type: EXPERIMENTAL
Intervention: Peer advisers (PADs) providing one-to-one psychosocial support and advice on self-management.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer advisers (PADs) as teachers on self-management to their peers with diabetes.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peer advisers (PADs) as committee members and advocates for diabetes.
Number of subjects: 0
Study: 18165091

Group type: EXPERIMENTAL
Intervention: Bag/balloon technology (ClearScan, ESI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Open‐shell technique
Number of subjects: 20
Study: 16173531

Group type: EXPERIMENTAL
Intervention: Acupuncture stimulation on GB34
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 10
Study: 12528106

Group type: COMPARATOR
Intervention: Brachial artery flow‐mediated dilatation (FMD)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Pulse wave analysis (PWA) - large artery compliance (C1)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Pulse wave analysis (PWA) - small artery compliance (C2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Modified Sharp scores
Number of subjects: 25
Study: 10373769

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure target < or = 90 mmHg
Number of subjects: 19000

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure target < or = 85 mmHg
Number of subjects: 19000

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure target < or = 80 mmHg
Number of subjects: 19000

Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid
Number of subjects: 19000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19000
Study: 8694040

Group type: EXPERIMENTAL
Intervention: Preinduction synthetic hygroscopic dilators (n = 112)
Number of subjects: 240

Group type: COMPARATOR
Intervention: No pretreatment (control group, n = 128)
Number of subjects: 240
Study: 1768542

Group type: EXPERIMENTAL
Intervention: Extradural bupivacaine (n = 9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Routine anaesthetic and surgical care (Control, n = 8)
Number of subjects: 17
Study: 7149895

Group type: EXPERIMENTAL
Intervention: In vivo exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response prevention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imaginal exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of all three procedures
Number of subjects: 0
Study: 31738927

Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham (without NIV)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 19
Study: 31025199

Group type: EXPERIMENTAL
Intervention: Interoceptive sensitivity (IS) in young adults
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Interoceptive sensitivity (IS) in older adults
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Physiological reactivity measures (electrodermal activity, heart rate, heart rate variability) during image viewing
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Subjective emotional responses to affect-inducing images
Number of subjects: 97
Study: 27845562

Group type: COMPARATOR
Intervention: Brushing with water only
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Brushing followed by soaking in Retainer Brite®
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Brushing followed by soaking in Kukis®
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Brushing followed by soaking in Corega®
Number of subjects: 60
Study: 25342290

Group type: EXPERIMENTAL
Intervention: Modufolin® (60 mg/m²)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Modufolin® (200 mg/m²)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Isovorin® (60 mg/m²)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Isovorin® (200 mg/m²)
Number of subjects: 32
Study: 24912842

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 236

Group type: COMPARATOR
Intervention: Levonorgestrel-releasing intrauterine system
Number of subjects: 236
Study: 22640677

Group type: EXPERIMENTAL
Intervention: Orthodontic treatment (treated group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Nontreated group (control)
Number of subjects: 200
Study: 19242392

Group type: EXPERIMENTAL
Intervention: 4% articaine 1:100,000, surgery initiated 5 minutes after anesthesia
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 4% articaine 1:100,000, surgery initiated 10 minutes after anesthesia
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 4% articaine 1:200,000, surgery initiated 5 minutes after anesthesia
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 4% articaine 1:200,000, surgery initiated 10 minutes after anesthesia
Number of subjects: 200
Study: 16463043

Group type: EXPERIMENTAL
Intervention: Multi-component physical conditioning programme (supervised resistance, aerobic, and balance exercises twice per week, plus home-based exercises once per week)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Normal daily activities (Control group)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Multi-component physical conditioning programme
Number of subjects: 38
Study: 15243747

Group type: EXPERIMENTAL
Intervention: Swimming economy factors (body length, body mass, propelling size, arm length, distance between center of mass and center of volume, body angle)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Normalized cost of swimming (CS(1.0) x BL(‐1))
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Combination of factors (BL, body mass, active drag factor, passive torque, drag efficiency, hydrostatic lift)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Size-independent factors (torque, floating abilities, swimming technique, active drag)
Number of subjects: 23
Study: 15530594

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral interventions to prevent STIs or UPs
Number of subjects: 2157

Group type: COMPARATOR
Intervention: Control group (prevent physical training injuries and cancer)
Number of subjects: 2157

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2157
Study: 10589537

Group type: EXPERIMENTAL
Intervention: Interferon-beta1b
Number of subjects: 718

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 718
Study: 8736219

Group type: EXPERIMENTAL
Intervention: Perisaccadic visual localization with brief (250 microseconds), bright (6000 cd/m2), binocular, gaze-point probe flashes.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probes presented monocularly at gaze, 6 deg left of gaze, and 6 deg right of gaze during saccades larger than 8 deg.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control trials with non-perisaccadic probes and feedback of pointing errors.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probes presented within 4 msec of the beginning of saccades.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probes presented during and after saccades.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Post-saccadic localization.
Number of subjects: 0
Study: 1646127

Group type: EXPERIMENTAL
Intervention: Invasive lobular carcinomas
Number of subjects: 171

Group type: COMPARATOR
Intervention: Non-lobular invasive carcinomas
Number of subjects: 171
Study: 6751132

Group type: EXPERIMENTAL
Intervention: mSAAST
Number of subjects: 625
Study: 31087075

Group type: EXPERIMENTAL
Intervention: Zolbetuximab-chemotherapy combination
Number of subjects: 263
Study: 29469654

Group type: EXPERIMENTAL
Intervention: Corinthian currant
Number of subjects: 11
Study: 26691396

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg and 0.75 mg
Number of subjects: 0
Study: 24356596

Group type: EXPERIMENTAL
Intervention: Intensive diabetes therapy (INT)
Number of subjects: 1441

Group type: COMPARATOR
Intervention: Conventional therapy (CON)
Number of subjects: 1441
Study: 22002829

Group type: EXPERIMENTAL
Intervention: Replacement group (supporting clients directly)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Backup group (supporting family members)
Number of subjects: 2
Study: 19834333

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 17602076

Group type: EXPERIMENTAL
Intervention: Tailored mailed print materials promoting fruit and vegetable consumption, reducing total/saturated fat intake, and increasing exercise for 10 months
Number of subjects: 543

Group type: COMPARATOR
Intervention: Nontailored mailed materials on diet and exercise available in the public domain for 10 months
Number of subjects: 543
Study: 15484202

Group type: EXPERIMENTAL
Intervention: Home-based moderate-intensity walking exercise program
Number of subjects: 119

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 119
Study: 11876713

Group type: EXPERIMENTAL
Intervention: Eradication treatment
Number of subjects: 686

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 686
Study: 10225539

Group type: EXPERIMENTAL
Intervention: Topical application of 25% metronidazole gel
Number of subjects: 56

Group type: COMPARATOR
Intervention: Systemic antibiotics (amoxicillin plus clavulanic acid 1 g/day for 14 days)
Number of subjects: 56
Study: 7602352

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 230
Study: 30182815

Group type: EXPERIMENTAL
Intervention: Drug-coated balloon
Number of subjects: 39

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 39
Study: 29763951

Group type: EXPERIMENTAL
Intervention: 4D‐CTA TACE
Number of subjects: 29

Group type: COMPARATOR
Intervention: Traditional TACE
Number of subjects: 29
Study: 27191794

Group type: EXPERIMENTAL
Intervention: Intermediate-acting insulin (IMI)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sliding-scale insulin (SSI)
Number of subjects: 26
Study: 25766081

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) for 4 weeks
Number of subjects: 64
Study: 22996139

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 53

Group type: COMPARATOR
Intervention: Education-only arm
Number of subjects: 53

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 53
Study: 19105058

Group type: EXPERIMENTAL
Intervention: Web-based prevention program (Student Body)
Number of subjects: 167
Study: 17766603

Group type: EXPERIMENTAL
Intervention: Acid buffering gel plus diaphragm
Number of subjects: 921

Group type: COMPARATOR
Intervention: Nonoxynol-9 spermicide plus diaphragm
Number of subjects: 921